Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

  1. Provencio, M.
  2. Serna-Blasco, R.
  3. Nadal, E.
  4. Insa, A.
  5. García-Campelo, M.R.
  6. Casal Rubio, J.
  7. Dómine, M.
  8. Majem, M.
  9. Rodríguez-Abreu, D.
  10. Martínez-Martí, A.
  11. De Castro Carpeño, J.
  12. Cobo, M.
  13. López Vivanco, G.
  14. Del Barco, E.
  15. Bernabé Caro, R.
  16. Viñolas, N.
  17. Barneto Aranda, I.
  18. Viteri, S.
  19. Pereira, E.
  20. Royuela, A.
  21. Calvo, V.
  22. Martín-López, J.
  23. García-García, F.
  24. Casarrubios, M.
  25. Franco, F.
  26. Sánchez-Herrero, E.
  27. Massuti, B.
  28. Cruz-Bermúdez, A.
  29. Romero, A.
  30. Show all authors +
Journal:
Journal of Clinical Oncology

ISSN: 1527-7755,  0732-183X

Year of publication: 2022

Volume: 71

Type: Article

DOI: 10.1200/JCO.21.02660 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus